Novo: reimbursement-changes will have consequences

It will have consequences to both diabetes patients and to Novo Nordisk if the Danish reimbursements-rules for two kinds of diabetes medicine are changed.

Foto: Novo Nordisk/PR

It will affect patients, as well as Novo Nordisk, if reimbursements for the insulin analogs and GLP-1 analogs will be altered, as the Danish Reimbursement Committee has suggested, according to Claus Dall Andersen, who is Head of Market Access in Novo Nordisk Denmark.

“We notice that various clauses have been set up for the groups to which Levemir and Victoza belong and we will study them now and take a good look at the underlying reasons for those clauses. But generally speaking we think it is a pity to impose limits on patients’ access to innovative medicine in this way,” he tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch


Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier